Orlistat: Clinically Proven Weight Loss Aid
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $4.52 | $135.54 (0%) | 🛒 Add to cart |
| 60 | $4.05 | $271.09 $242.98 (10%) | 🛒 Add to cart |
| 90 | $3.88 | $406.63 $349.40 (14%) | 🛒 Add to cart |
| 120 | $3.81
Best per cap | $542.18 $456.84 (16%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $1.97 | $59.24 (0%) | 🛒 Add to cart |
| 60 | $1.54 | $118.48 $92.37 (22%) | 🛒 Add to cart |
| 90 | $1.39 | $177.71 $125.50 (29%) | 🛒 Add to cart |
| 120 | $1.31 | $236.95 $157.63 (33%) | 🛒 Add to cart |
| 180 | $1.24 | $355.43 $223.90 (37%) | 🛒 Add to cart |
| 270 | $1.20 | $533.14 $323.30 (39%) | 🛒 Add to cart |
| 360 | $1.17
Best per cap | $710.86 $421.69 (41%) | 🛒 Add to cart |
Synonyms | |||
Orlistat is a lipase inhibitor medication approved for weight management in adults with a body mass index (BMI) of 30 or greater, or 27 or greater with associated risk factors such as hypertension, type 2 diabetes, or dyslipidemia. It functions by inhibiting gastrointestinal lipases, reducing dietary fat absorption by approximately 30%. This non-systemic agent supports sustainable weight reduction when combined with a reduced-calorie diet, promoting long-term health improvements and mitigating obesity-related comorbidities.
Features
- Active ingredient: Orlistat 120 mg per capsule
- Mechanism: Reversible inhibitor of gastric and pancreatic lipases
- Administration: Oral capsule, taken with meals
- Prescription status: Available in prescription strength (120 mg) and over-the-counter (60 mg) formulations
- Non-systemic action: Minimal absorption into bloodstream; acts locally in the GI tract
- Compatibility: Suitable for use alongside a medically supervised weight management plan
Benefits
- Promotes clinically significant weight loss—typically 5–10% of initial body weight within six months
- Reduces absorption of dietary fats, directly targeting caloric intake from lipids
- Lowers LDL cholesterol and improves lipid profiles independent of weight loss
- May improve glycemic control and insulin sensitivity in patients with type 2 diabetes
- Supports long-term weight maintenance when combined with lifestyle modifications
- Non-habit forming with no known potential for abuse or dependence
Common use
Orlistat is indicated for obesity management in conjunction with a mildly hypocaloric diet. It is commonly prescribed for patients who have not achieved target weight loss through diet and exercise alone. Typical users include individuals with obesity-related comorbidities such as hypertension, hypercholesterolemia, or impaired glucose tolerance. The medication is often incorporated into multidisciplinary weight management programs that include nutritional counseling and physical activity guidance.
Dosage and direction
The recommended dosage is one 120 mg capsule taken orally three times daily with each main meal containing fat. Administration should occur during the meal or up to one hour after eating. If a meal is missed or contains no fat, the dose should be omitted. The medication works by blocking fat absorption from that specific meal only. Maximum daily dosage should not exceed 360 mg (three capsules). Treatment beyond two years should be reevaluated based on continued benefit-risk assessment.
Precautions
Patients should maintain a nutritionally balanced, reduced-calorie diet containing approximately 30% of calories from fat to minimize gastrointestinal effects. Fat-soluble vitamin (A, D, E, K) levels should be monitored during prolonged therapy, with supplementation recommended if deficiency occurs. Use with caution in patients with history of hyperoxaluria or calcium oxalate nephrolithiasis. Not recommended for use during pregnancy or breastfeeding. Periodic monitoring of weight loss progress and potential adverse effects is advised.
Contraindications
Chronic malabsorption syndrome or cholestasis; known hypersensitivity to orlistat or any component of the formulation; organ transplant recipients receiving cyclosporine therapy; patients with reduced gallbladder function or history of biliary disease; concurrent use with acarbose; pediatric patients under 12 years of age.
Possible side effects
Common gastrointestinal effects include oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation, and fecal incontinence. These effects are generally dose-dependent and diminish with continued use. Less frequently reported effects include abdominal pain/discomfort, nausea, vomiting, and rectal pain. Rare cases of hepatic injury, hypersensitivity reactions, and oxalate nephropathy have been reported. Dental and gum disorders may occur with long-term use.
Drug interaction
Significantly reduces absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene—separate supplementation by at least 2 hours. May decrease plasma levels of amiodarone, anticonvulsants (particularly valproate), and thyroid hormones. Avoid concurrent use with cyclosporine (separate administration by at least 3 hours). Potential interaction with warfarin requiring increased INR monitoring. May affect absorption of oral contraceptives—recommend additional contraceptive methods.
Missed dose
If a dose is missed, resume with the next scheduled dose with a fat-containing meal. Do not double the dose to make up for a missed administration. The medication’s effect is meal-specific, so extra doses will not provide additional benefit and may increase side effects.
Overdose
No serious adverse events reported from acute overdose. Maximum daily dose studied was 800 mg without significant additional effects. Management should focus on symptomatic treatment of gastrointestinal effects. Maintain adequate hydration and monitor for potential fat-soluble vitamin deficiencies with chronic excessive use.
Storage
Store at room temperature (15–30°C/59–86°F) in original container. Protect from moisture and light. Keep tightly closed and out of reach of children. Do not use after expiration date printed on packaging. Do not transfer to alternative containers as moisture protection may be compromised.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual results may vary. Orlistat should be used under medical supervision as part of a comprehensive weight management program. Consult a healthcare professional before starting any weight loss medication to determine appropriate treatment based on individual health status and needs.
Reviews
Clinical studies demonstrate that orlistat produces significantly greater weight loss than placebo when combined with lifestyle modification. In a 4-year XENDOS study, orlistat reduced diabetes incidence by 37% in obese patients with impaired glucose tolerance. Patient-reported outcomes indicate improved quality of life measures and satisfaction with weight loss results, though gastrointestinal side effects remain the most common reason for discontinuation. Meta-analyses confirm its efficacy and safety profile for long-term obesity management.